Aqylon Nexus Ltd
AQYLONAqylon Nexus Ltd's balance sheet is under water — net worth is negative, so it owes more than it owns. This is a distressed, high-risk situation — the equity can be wiped by dilution or restructuring before operations recover. Not a value setup.
Biggest watch item: the P/E sits at the 100th percentile of its own range — the multiple has already done part of the work.
The price is in a downtrend (23 weeks in) while the P/E sits at the 100th percentile of its own 1-year range. But the balance sheet is under water: net worth is negative, so shareholders sit behind everyone the company owes. What settles it: whether the business can earn its way back to positive equity before dilution or restructuring gets there first.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Aqylon Nexus Ltd trades at ₹21.2, in a downtrend and 23 weeks into that stage. That is −66.6% against its own 200-day average. It sits at 0% of a 52-week range of ₹21 to ₹203. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (15 weeks and counting).
Today the stock is in a downtrend — week 23 of stage 4, confirmed. At ₹21.2 it trades −66.6% versus its 200-day average and sits at 0% of its 52-week range (₹21–₹203).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved −26% while the NIFTY 500 moved +248% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (15 weeks and counting; last ahead the week of 2026-06-17) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Aqylon Nexus Ltd trades at 759.0× P/E, about the priciest it has ever traded. Its long-run median P/E is 108.4×, measured across 1.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 759.0× is about the priciest it has ever traded, against a long-run median of 108.4× measured over 1.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Aqylon Nexus Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 6 quarters across 0 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
The return-on-capital curve is not shown — net worth is negative, so a return on capital is not a meaningful number in any basis. This is a distressed balance sheet, and the stage is read from the growth curves alone.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +116.7% | — | — | −19.1% |
| EPS | — | — | — | +36.8% |
| Share price | −78.7% | +446.7% | +162.6% | −2.2% |
4-Factor Sector Score
45.9/100 — rank 18 of 36 in Miscellaneous · 72% evidence confidence
Aqylon Nexus Ltd scores 45.9 out of 100 against the 36 companies it is compared with in Miscellaneous, ranking 18. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 18.5 + 18.8 + 8.6 + 0 = 45.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Aqylon Nexus Ltd reported ₹8.5 Cr of revenue in the Jun 26 quarter. Over 10 years it has compounded at −19.1% a year. The last full year, FY26, came in at ₹13.0 Cr. The last four reported quarters add to ₹21.6 Cr.
FY26 revenue came in at ₹13.0 Cr (+116.7% on the year), capping 10 years at −19.1% compound. The latest quarter (Jun 26) printed ₹8.5 Cr, null year on year.
Pace check: the last four quarters averaged +176.8% growth against the decade's −19.1% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +328.5% over the last 4 quarters against +194.2%/yr over the last 8 — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Aqylon Nexus Ltd's operating margin is 58.0% in the Jun 26 quarter, +2,358.0 percentage points against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged −210.0% to 100.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 58.0%, +2,358.0 pp against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged −210.0%–100.0%.
Why the margin moved: operating margin went +2,358.0 pp year on year while gross margin went +27.4 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Aqylon Nexus Ltd earned ₹4.3 Cr of net profit in the Jun 26 quarter. Full-year FY26 profit was ₹6.0 Cr. That is 50.3% of the quarter's revenue. The same quarter a year earlier lost ₹1.8 Cr. 6 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹4.3 Cr, null year on year. On the full year, FY26 printed ₹6.0 Cr (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 394% of Aqylon Nexus Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹7.0 Cr of operating cash against ₹6.0 Cr of profit. After ₹−8.0 Cr of capital spending, ₹15.0 Cr was left as free cash.
FY26: operating cash of ₹7.0 Cr against reported profit of ₹6.0 Cr, leaving free cash of ₹15.0 Cr after ₹−8.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 394% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 394%: the cash cycle stretched 36 days between FY18 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Aqylon Nexus Ltd's cash conversion cycle runs 80 days in FY26, up from 44 days in FY18. Capital spending ran ₹−74.0 Cr over the last 3 years. At FY26 sales of ₹13.0 Cr each day of that cycle holds about ₹0.0 Cr, so roughly ₹3.0 Cr sits inside the business at any moment.
FY26: debtors at 80 days, inventory at 0 days — roughly 0.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 80 days, looser than FY18's 44.
In money terms: at FY26 sales of ₹13.0 Cr, each day of the cycle holds about ₹0.0 Cr — so the 80-day loop keeps roughly ₹3.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹−74.0 Cr over the last 3 fiscal years against ₹19.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Aqylon Nexus Ltd earns a ROCE of 131% in FY26. That is up from a trough of −91% in FY19. Return on invested capital clears the cost of that capital by −3.0 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 46.2% net margin on 0.93× asset turns.
FY26 ROCE is 131%, recovered from a FY19 trough of −91% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 46.2% net margin × 0.93× asset turns × −2.33× balance-sheet leverage ≈ −100.1% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 9.0% − 12.0% = a −3.0 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Aqylon Nexus Ltd's net worth is negative — it owes more than it owns — so a debt-to-equity ratio is not meaningful here. On the annual view that ratio went from −2.32 in FY22 to −3.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹18.0 Cr against shareholder equity of ₹−6.0 Cr — a debt-to-equity of −3.00. On the annual view, debt-to-equity went from −2.32 (FY22) to −3.00 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 27.4 points of Aqylon Nexus Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 27.6% of the company. Promoters moved −13.9 points over the same window, to 45.6%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +27.4 points over 8 quarters to 27.6%; Promoters: −13.9 points over 8 quarters to 45.6%; Foreign institutions: +8.4 points over 8 quarters to 8.4%.
Why the register moved: domestic institutions drove it (+27.4 points), absorbed on the other side by promoters (−13.9 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Aqylon Nexus Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Gulshan Polyols LtdGULPOLY | 70.7/100Favorable setup87% evidence | ASLEEP | 27.5/35 Revenue 9.4% · PAT 100% · OPM change 7 pp 95% evidence | 19.2/25 ROCE 18.6% · OPM 13% 95% evidence | 13.2/20 P/E 7.4× · PEG — 50% evidence | 10.8/20 RS sector 3.7% · RS bench 7% · 1Y 8.8%5 of 12 weeks ahead 100% evidence |
| Exact sum: 27.5 + 19.2 + 13.2 + 10.8 = 70.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Sagility LtdSAGILITY | 67.6/100Favorable setup87% evidence | TURNING | 24.7/35 Revenue 29.4% · PAT 49.3% · OPM change 0 pp 100% evidence | 15.8/25 ROCE 13.4% · OPM 22% 100% evidence | 13.5/20 P/E 20.6× · PEG 1.08 65% evidence | 13.6/20 RS sector 7.2% · RS bench 1.7% · 1Y 5.3%3 of 10 weeks ahead 70% evidence |
| Exact sum: 24.7 + 15.8 + 13.5 + 13.6 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3IIRM Holdings India Ltd526530 | 64.2/100Mixed-positive evidence75% evidence | LEADER | 16.3/35 Revenue 14.9% · PAT 12.7% · OPM change 1.1 pp 95% evidence | 19.0/25 ROCE 20.4% · OPM 24.6% 76% evidence | 9.9/20 P/E 39.9× · PEG — 15% evidence | 19.0/20 RS sector 42.8% · RS bench 47.3% · 1Y 79.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 19 + 9.9 + 19 = 64.2 · Decision use: Price leads the evidence: RS versus the benchmark is 47.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 4Exhicon Events Media Solutions Ltd543895 | 63.7/100Thin evidence · provisional60% evidence | TURNING | 19.0/35 Revenue 100% · PAT 100% · OPM change 0 pp 48% evidence | 20.1/25 ROCE 29.5% · OPM 28% 76% evidence | 13.4/20 P/E 19.2× · PEG — 50% evidence | 11.2/20 RS sector 2.2% · RS bench -1.9% · 1Y -4.8%2 of 10 weeks ahead 70% evidence |
| Exact sum: 19 + 20.1 + 13.4 + 11.2 = 63.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Aeroflex Enterprises LtdAEROENTER | 62.8/100Mixed-positive evidence87% evidence | LEADER | 19.7/35 Revenue 27.5% · PAT 100% · OPM change -5 pp 95% evidence | 14.9/25 ROCE 12.6% · OPM 9% 95% evidence | 9.0/20 P/E 10.2× · PEG — 50% evidence | 19.2/20 RS sector 38.8% · RS bench 42.9% · 1Y 57.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 14.9 + 9 + 19.2 = 62.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Global Education LtdGLOBAL | 62.5/100Mixed-positive evidence80% evidence | TURNING | 14.2/35 Revenue 28.2% · PAT 3.3% · OPM change 0.3 pp 95% evidence | 19.8/25 ROCE 29.2% · OPM 41% 95% evidence | 10.1/20 P/E 24.8× · PEG — 15% evidence | 18.4/20 RS sector 32.4% · RS bench 36.9% · 1Y 97.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 19.8 + 10.1 + 18.4 = 62.5 · Decision use: Price leads the evidence: RS versus the benchmark is 36.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 7Take Solutions LtdTAKE | 58.7/100Thin evidence · provisional57% evidence | 24.7/35 Revenue — · PAT 100% · OPM change 2932.2 pp 57% evidence | 8.5/25 ROCE 11.2% · OPM — 80% evidence | 8.5/20 P/E 3222× · PEG — 15% evidence | 17.0/20 RS sector 71.1% · RS bench 71.4% · 1Y 300.4%11 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 24.7 + 8.5 + 8.5 + 17 = 58.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8R K Swamy LtdRKSWAMY | 57.1/100Mixed-positive evidence65% evidence | 22.5/35 Revenue 14.3% · PAT 17.3% · OPM change 2.6 pp 95% evidence | 15.6/25 ROCE 12.3% · OPM 10.4% 95% evidence | 10.7/20 P/E 19.5× · PEG — 15% evidence | 8.3/20 RS sector — · RS bench -16.7% · 1Y —4 of 5 weeks ahead to 2026-08-16 25% evidence | |
| Exact sum: 22.5 + 15.6 + 10.7 + 8.3 = 57.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Aegis Vopak Terminals LtdAEGISVOPAK | 55.8/100Mixed-positive evidence60% evidence | BREAKING OUT | 21.9/35 Revenue 25.9% · PAT 40.9% · OPM change 2 pp 95% evidence | 13.2/25 ROCE 7.6% · OPM 77% 76% evidence | 8.9/20 P/E 121× · PEG — 15% evidence | 11.8/20 RS sector — · RS bench 25.5% · 1Y 24.5%10 of 10 weeks ahead 25% evidence |
| Exact sum: 21.9 + 13.2 + 8.9 + 11.8 = 55.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Parin Enterprises LtdPARIN | 52.2/100Mixed-positive evidence63% evidence | FADING | 19.4/35 Revenue 100% · PAT 100% · OPM change -3 pp 48% evidence | 11.6/25 ROCE 10.8% · OPM 9% 95% evidence | 9.1/20 P/E 117× · PEG — 15% evidence | 12.1/20 RS sector 5.1% · RS bench 8.7% · 1Y 46.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 11.6 + 9.1 + 12.1 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Eveready Industries India LtdEVEREADY | 50.9/100Mixed-positive evidence94% evidence | TURNING | 18.9/35 Revenue 8.7% · PAT 100% · OPM change 1 pp 100% evidence | 13.6/25 ROCE 17.2% · OPM 15% 100% evidence | 9.0/20 P/E 16.6× · PEG 2.1 100% evidence | 9.4/20 RS sector -9.5% · RS bench 8.6% · 1Y -22.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 18.9 + 13.6 + 9 + 9.4 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12GMR Airports LtdGMRAIRPORT | 50.8/100Mixed-positive evidence74% evidence | ASLEEP | 22.7/35 Revenue 38.8% · PAT 100% · OPM change 1 pp 74% evidence | 11.3/25 ROCE 11.6% · OPM 37% 100% evidence | 8.7/20 P/E 184× · PEG — 15% evidence | 8.1/20 RS sector -2.8% · RS bench 0.5% · 1Y 14%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.7 + 11.3 + 8.7 + 8.1 = 50.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Anzen India Energy Yield Plus TrustANZEN | 50.3/100Mixed-positive evidence60% evidence | TURNING | 20.7/35 Revenue 100% · PAT 100% · OPM change -9 pp 95% evidence | 9.1/25 ROCE 3.3% · OPM 80% 76% evidence | 9.3/20 P/E 99.7× · PEG — 15% evidence | 11.2/20 RS sector — · RS bench 7.3% · 1Y 8.7%1 of 10 weeks ahead 25% evidence |
| Exact sum: 20.7 + 9.1 + 9.3 + 11.2 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Jai Corp LtdJAICORPLTD | 48.3/100Mixed-negative evidence74% evidence | BASING | 19.6/35 Revenue 2.7% · PAT -40.4% · OPM change 9 pp 95% evidence | 11.4/25 ROCE 11.8% · OPM 15% 95% evidence | 10.9/20 P/E 17.8× · PEG — 15% evidence | 6.4/20 RS sector -8.2% · RS bench -19.2% · 1Y -40.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 19.6 + 11.4 + 10.9 + 6.4 = 48.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Inox Green Energy Services LtdINOXGREEN | 48.0/100Mixed-negative evidence75% evidence | ASLEEP | 22.2/35 Revenue 16.5% · PAT 100% · OPM change -13.2 pp 95% evidence | 9.1/25 ROCE 8.4% · OPM -2.2% 76% evidence | 9.7/20 P/E 58.4× · PEG — 15% evidence | 7.0/20 RS sector -6% · RS bench -2.9% · 1Y 19.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 9.1 + 9.7 + 7 = 48 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16TCC Concept LtdTCC | 47.5/100Mixed-negative evidence81% evidence | BASING | 16.6/35 Revenue 100% · PAT 51.1% · OPM change -45 pp 95% evidence | 11.8/25 ROCE 5.7% · OPM 36% 95% evidence | 14.1/20 P/E 20× · PEG — 50% evidence | 5.0/20 RS sector -17.6% · RS bench -31.9% · 1Y -89.7%0 of 11 weeks ahead 70% evidence |
| Exact sum: 16.6 + 11.8 + 14.1 + 5 = 47.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Prozone Realty LtdPROZONER | 46.4/100Mixed-negative evidence80% evidence | TURNING | 17.0/35 Revenue -9.9% · PAT 100% · OPM change 8.2 pp 95% evidence | 6.4/25 ROCE -1% · OPM -35.6% 95% evidence | 9.6/20 P/E 62.1× · PEG — 15% evidence | 13.4/20 RS sector -0.3% · RS bench 3.1% · 1Y 21.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 6.4 + 9.6 + 13.4 = 46.4 · Decision use: Price leads the evidence: RS versus the benchmark is 3.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18Aqylon Nexus Ltdthis pageAQYLON | 45.9/100Mixed-negative evidence72% evidence | BASING | 18.5/35 Revenue 100% · PAT 100% · OPM change 2358 pp 71% evidence | 18.8/25 ROCE 131% · OPM 58% 95% evidence | 8.6/20 P/E 759× · PEG — 15% evidence | 0.0/20 RS sector -76.3% · RS bench -75.3% · 1Y -79.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 18.8 + 8.6 + 0 = 45.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Jindal Photo LtdJINDALPHOT | 43.3/100Mixed-negative evidence77% evidence | ASLEEP | 20.4/35 Revenue 100% · PAT -80% · OPM change 15 pp 95% evidence | 10.1/25 ROCE -1.4% · OPM 98% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.8/20 RS sector -19.1% · RS bench -16.2% · 1Y -14.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 10.1 + 10 + 2.8 = 43.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Shipping Corporation of India Land & Assets LtdSCILAL | 42.8/100Mixed-negative evidence80% evidence | BASING | 24.2/35 Revenue 23.8% · PAT 100% · OPM change 13 pp 95% evidence | 5.0/25 ROCE 1.3% · OPM -14% 95% evidence | 9.5/20 P/E 62.3× · PEG — 15% evidence | 4.1/20 RS sector -17.6% · RS bench -14.8% · 1Y -26.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 24.2 + 5 + 9.5 + 4.1 = 42.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -17.6% and the one-year return is -26.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 21TruAlt Bioenergy LtdTRUALT | 40.3/100Mixed-negative evidence63% evidence | ASLEEP | 10.7/35 Revenue 1.8% · PAT -8.1% · OPM change 7 pp 100% evidence | 9.3/25 ROCE 10.4% · OPM 21% 100% evidence | 10.3/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -21.6%2 of 12 weeks ahead 0% evidence |
| Exact sum: 10.7 + 9.3 + 10.3 + 10 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22GKW LtdGKWLIMITED | 39.2/100Mixed-negative evidence71% evidence | ASLEEP | 10.9/35 Revenue -13.5% · PAT 0% · OPM change -2 pp 95% evidence | 9.2/25 ROCE 0.5% · OPM 84% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.1/20 RS sector -0.9% · RS bench -4.5% · 1Y -9.4%2 of 10 weeks ahead 70% evidence |
| Exact sum: 10.9 + 9.2 + 10 + 9.1 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Unitech LtdUNITECH | 36.8/100Mixed-negative evidence69% evidence | BASING | 18.0/35 Revenue 45.3% · PAT -10% · OPM change 15 pp 71% evidence | 3.5/25 ROCE 0.1% · OPM 6% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.3/20 RS sector -22.3% · RS bench -19.7% · 1Y -39.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 3.5 + 10 + 5.3 = 36.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Kaveri Seed Company LtdKSCL | 35.9/100Mixed-negative evidence94% evidence | BASING | 11.3/35 Revenue 1.4% · PAT -21.7% · OPM change 1 pp 100% evidence | 14.4/25 ROCE 18.8% · OPM 40% 100% evidence | 4.7/20 P/E 14.8× · PEG 3.12 100% evidence | 5.5/20 RS sector -17.2% · RS bench -19.8% · 1Y -40%1 of 11 weeks ahead 70% evidence |
| Exact sum: 11.3 + 14.4 + 4.7 + 5.5 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Delta Corp LtdDELTACORP | 35.4/100Mixed-negative evidence81% evidence | BASING | 9.7/35 Revenue -9.3% · PAT -80% · OPM change -3 pp 95% evidence | 8.6/25 ROCE 5.1% · OPM 18% 95% evidence | 12.0/20 P/E 9.4× · PEG — 50% evidence | 5.1/20 RS sector -18.1% · RS bench -18.3% · 1Y -36.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 9.7 + 8.6 + 12 + 5.1 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Stanley Lifestyles LtdSTANLEY | 30.0/100Adverse evidence74% evidence | BASING | 6.6/35 Revenue -5.6% · PAT -80% · OPM change -3.4 pp 95% evidence | 10.8/25 ROCE 6.4% · OPM 17.3% 95% evidence | 9.2/20 P/E 112× · PEG — 15% evidence | 3.4/20 RS sector -43.7% · RS bench -25.2% · 1Y -54.7%3 of 10 weeks ahead 70% evidence |
| Exact sum: 6.6 + 10.8 + 9.2 + 3.4 = 30 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Embassy Developments LtdEMBDL | 26.2/100Adverse evidence64% evidence | BASING | 5.9/35 Revenue -46.6% · PAT -80% · OPM change -58.4 pp 71% evidence | 3.4/25 ROCE -2.4% · OPM -60% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.9/20 RS sector -18.4% · RS bench -15.8% · 1Y -42.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 5.9 + 3.4 + 10 + 6.9 = 26.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28RattanIndia Enterprises LtdRTNINDIA | 17.5/100Adverse evidence74% evidence | ASLEEP | 2.7/35 Revenue 2.1% · PAT -80% · OPM change -23.9 pp 100% evidence | 1.0/25 ROCE -4.8% · OPM 2.1% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.8/20 RS sector -32.1% · RS bench -24.4% · 1Y -55.3%1 of 10 weeks ahead 70% evidence |
| Exact sum: 2.7 + 1 + 10 + 3.8 = 17.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Central Mine Planning & Design Institute LtdCMPDI | 63.2/100Thin evidence · provisional40% evidence | ASLEEP | 22.4/35 Revenue — · PAT — · OPM change 8 pp 34% evidence | 20.6/25 ROCE 38.1% · OPM 30% 100% evidence | 10.2/20 P/E 23.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 9 weeks ahead 0% evidence |
| Exact sum: 22.4 + 20.6 + 10.2 + 10 = 63.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30FlySBS Aviation LtdFLYSBS | 57.7/100Thin evidence · provisional41% evidence | BREAKING OUT | 15.4/35 Revenue — · PAT — · OPM change -8 pp 26% evidence | 19.4/25 ROCE 32.5% · OPM 21% 95% evidence | 10.6/20 P/E 20× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 43.9% · 1Y 14.1%6 of 10 weeks ahead 25% evidence |
| Exact sum: 15.4 + 19.4 + 10.6 + 12.3 = 57.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 31Qualitek Labs Ltd544091 | 54.3/100Thin evidence · provisional29% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change -3 pp 7% evidence | 15.1/25 ROCE 11.9% · OPM 26% 76% evidence | 9.8/20 P/E 44.2× · PEG — 15% evidence | 12.1/20 RS sector — · RS bench 42.7% · 1Y —4 of 6 weeks ahead 25% evidence |
| Exact sum: 17.3 + 15.1 + 9.8 + 12.1 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Shree Vasu Logistics LtdSVLL | 52.6/100Thin evidence · provisional50% evidence | BREAKING OUT | 18.3/35 Revenue — · PAT — · OPM change 0.8 pp 26% evidence | 16.0/25 ROCE 12.9% · OPM 25.8% 95% evidence | 8.8/20 P/E 126× · PEG — 15% evidence | 9.5/20 RS sector -16.1% · RS bench 17.5% · 1Y 2.2%10 of 10 weeks ahead 70% evidence |
| Exact sum: 18.3 + 16 + 8.8 + 9.5 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Indiqube Spaces LtdINDIQUBE | 49.7/100Thin evidence · provisional49% evidence | BREAKING OUT | 18.9/35 Revenue 38.9% · PAT 30.4% · OPM change 0 pp 71% evidence | 9.3/25 ROCE 6.4% · OPM 61% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.5/20 RS sector — · RS bench 10.4% · 1Y -11.8%5 of 10 weeks ahead 25% evidence |
| Exact sum: 18.9 + 9.3 + 10 + 11.5 = 49.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Maagh Advertising & Marketing Services Ltd543624 | 49.5/100Thin evidence · provisional35% evidence | 18.4/35 Revenue — · PAT — · OPM change 275.6 pp 32% evidence | 9.1/25 ROCE -0.4% · OPM 55.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.0/20 RS sector — · RS bench 37% · 1Y —7 of 9 weeks ahead to 2025-03-19 25% evidence | |
| Exact sum: 18.4 + 9.1 + 10 + 12 = 49.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 35Tandhan Industries Ltd512062 | 46.3/100Thin evidence · provisional33% evidence | BREAKING OUT | 20.2/35 Revenue — · PAT 100% · OPM change — 33% evidence | 6.7/25 ROCE -0.3% · OPM 15.8% 76% evidence | 9.4/20 P/E 71.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —10 of 10 weeks ahead 0% evidence |
| Exact sum: 20.2 + 6.7 + 9.4 + 10 = 46.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 36Shree Rama Newsprint LtdRAMANEWS | 45.4/100Thin evidence · provisional46% evidence | 14.1/35 Revenue -20% · PAT 69.8% · OPM change -8 pp 40% evidence | 6.1/25 ROCE 1.9% · OPM 8% 71% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.2/20 RS sector 9.7% · RS bench 10.5% · 1Y 21.7%11 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 14.1 + 6.1 + 10 + 15.2 = 45.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Aqylon Nexus Ltd's share price today?
Aqylon Nexus Ltd trades at ₹21.2, −78.7% over the past year. The company is valued at ₹539 Cr. The stock sits at the very bottom of its 52-week range (₹21–₹203), −66.6% versus its 200-day average. On the tape, the price is in a downtrend, 23 weeks in. — as of 11 September 2026.
What were Aqylon Nexus Ltd's latest quarterly results?
Aqylon Nexus Ltd reported revenue of ₹8.5 Cr and net profit of ₹4.3 Cr for the Jun 26 quarter. Earnings per share were ₹0.17. The operating margin was 58.0%, 2,358.0 pp higher than a year earlier. — as of 11 September 2026.
What is Aqylon Nexus Ltd's revenue?
Aqylon Nexus Ltd reported revenue of ₹8.5 Cr in the Jun 26 quarter. For the full FY26 fiscal year, revenue was ₹13.0 Cr (+116.7%). Over the last 10 years revenue compounded at −19.1% a year. — as of 11 September 2026.
What is Aqylon Nexus Ltd's profit?
Aqylon Nexus Ltd earned ₹4.3 Cr of net profit in the Jun 26 quarter. Full-year FY26 profit was ₹6.0 Cr. The operating margin ran 58.0% in the latest quarter. — as of 11 September 2026.
What is Aqylon Nexus Ltd's market cap?
Aqylon Nexus Ltd's market capitalisation is ₹539 Cr at a share price of ₹21.2. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Aqylon Nexus Ltd's P/E ratio?
Aqylon Nexus Ltd trades at a P/E of 759.0×, at the most expensive it has been in 1 years, against a long-run median of 108.4×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Aqylon Nexus Ltd pay a dividend?
Not in its latest year — Aqylon Nexus Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 4 of its last 13 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Aqylon Nexus Ltd overvalued?
On its own history, Aqylon Nexus Ltd looks expensive: its P/E of 759.0× sits at the most expensive it has been in 1 years (long-run median 108.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
How is Aqylon Nexus Ltd performing?
Aqylon Nexus Ltd is in a downtrend, 23 weeks in. Against the NIFTY 500 it has been behind on a trailing-13-week view for 15 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
Is Aqylon Nexus Ltd in an uptrend?
No — the price is in a downtrend (week 23 of stage 4), trading −66.6% versus its 200-day average and at the very bottom of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Aqylon Nexus Ltd beating the market?
Not lately — on a trailing-13-week view Aqylon Nexus Ltd is currently behind the NIFTY 500 (15 weeks and counting; last ahead the week of 2026-06-17), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved −26% against the NIFTY 500's +248% — behind the index over the full window. — as of 11 September 2026.
Will Aqylon Nexus Ltd's share price go up?
This page publishes no price forecast for Aqylon Nexus Ltd. What it measures instead: the share price is ₹21.2, the price is in a downtrend 23 weeks in. Its P/E of 759.0× sits at the 100th percentile of its own 1-year range. — as of 11 September 2026.
Who owns Aqylon Nexus Ltd?
Promoters hold 45.6% of Aqylon Nexus Ltd, foreign institutions 8.4%, domestic institutions 27.6% and the public 18.4% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 27.4 points over 8 quarters. — as of 11 September 2026.
Does Aqylon Nexus Ltd have too much debt?
No — Aqylon Nexus Ltd's debt-to-equity is −3.00, and operating profit covers the interest bill 0×. FY26 borrowings were ₹18.0 Cr against equity of ₹−6.0 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Aqylon Nexus Ltd's capex?
Aqylon Nexus Ltd spent ₹−74.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹−8.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Aqylon Nexus Ltd's cash flow?
Aqylon Nexus Ltd generated ₹7.0 Cr of operating cash flow in FY26 and ₹15.0 Cr of free cash flow after ₹−8.0 Cr of capital spending. Reported profit that year was ₹6.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Aqylon Nexus Ltd's profit real cash?
Yes — over the last 3 fiscal years, 394% of Aqylon Nexus Ltd's reported profit arrived as operating cash. Though the latest year ran at 117% — the trend is the thing to watch. In FY26, operating cash was ₹7.0 Cr against reported profit of ₹6.0 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Aqylon Nexus Ltd in its business cycle?
Aqylon Nexus Ltd's FY26 operating margin was 4.1%, against a 10-year band of −210.0%–100.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 58.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Aqylon Nexus Ltd story?
Biggest watch item: the P/E sits at the 100th percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Aqylon Nexus Ltd a stock worth studying right now?
This is not investment advice. The machine read: Aqylon Nexus Ltd's balance sheet is under water — net worth is negative, so it owes more than it owns. This is a distressed, high-risk situation — the equity can be wiped by dilution or restructuring before operations recover. Not a value setup. The sharpest open question: whether the business can earn its way back to positive equity before dilution or restructuring gets there first. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!